The Committee for Medicinal Products for Human Use (CHMP) supports Novartis‘ Enerzair Breezhaler, the first triple-combination asthma therapy that includes an optional digital sensor.
Enerzair (formerly QVM149) consists of long-acting beta-agonist indacaterol (LABA), long-acting muscarinic antagonist glycopyrronium (LAMA) and inhaled corticosteroid mometasone furoate.
The sensor in the Breezhaler device is a turning point that connects to the base of the Breezhaler device and collects data on the use of the inhaler, sending data remotely to an app on a smartphone or similar device. So, this makes the data more accurate, it’s like using a thermometer to find out body temperature. In addition, this optional sensor connects to the base of the Breezhaler device and collects data on the use of the inhaler, sending the data remotely to an app on a smartphone or similar device.
Novartis’ Enerzair approval will have an impact on rival GSK which has already obtained approval on Trelegy (fluticasone furoate / umeclidinium / vilanterol) – another LABA / LAMA / ICS combination approved for chronic obstructive pulmonary disease (COPD) and was filed for approval as an asthma therapy in Europe in February , therefore it appears that it should be several months behind the Novartis drug.
Novartis is ready to hit the market two or three months before Trelegy (Trelegy Sales to climb up to $1.4 bn by 2024) for uncontrolled asthma. It has another claim to fame, as Novartis claims it is the first asthma therapy with an optional digital sensor and app to improve compliance.
Mellalta Meets has accumulated some vital information that can be of great use to anyone in the field of uncontrolled asthma.